136 results about "Scopolamine" patented technology

An implant for use with an eye comprises an implantable structure and a therapeutic agent. The therapeutic agent is deliverable from the structure into the eye so as to therapeutically effect and / or stabilize a refractive property of the eye. In many embodiments, the refractive property of the eye may comprise at least one of myopia, hyperopia or astigmatism. The therapeutic agent can comprise a composition that therapeutically effects or stabilizes the refractive property of the eye. The therapeutic agent may comprise at least one of a mydriatic or a cycloplegic drug. For example, the therapeutic agent may include a cycloplegic that comprises at least one of atropine, cyclopentolate, succinylcholine, homatropine, scopolamine, or tropicamide. In many embodiments, a retention element can be attached to the structure to retain the structure along a natural tissue surface.

Compositions and methods of treating or preventing hot flashes, night sweats, and / or insomnia in a subject that involve scopolamine are disclosed. For example, methods of treating hot flashes, night sweats, and / or insomnia in a subject that involve transdermal delivery of scopolamine are set forth herein.

Administering to a patient an anticholinergic medication comprising scopolamine and hydroxyzine can alleviate the symptoms of nicotine withdrawal. Used in conjunction with pre- and post-administration counseling, smoking cessation rates may be significantly improved.

Non-effervescent pharmaceutical compositions having at least one particle of carbonate coated by a layer of polyethylene glycol that substantially covers the at least one carbonate particle are described. Compositions are also described where the compositions include a weakly basic therapeutic agent, a first pH-modifying agent having at least one particle of carbonate coated by a layer of polyethylene glycol, and a second pH-modifying agent. The weakly basic therapeutic agent could be, but is not limited to, zolpidem or scopolamine. Compositions including zolpidem and scopolamine are used to treat insomnia and depression, respectively.

One embodiment of an aspect of the present invention is a method for lessening the symptoms of depression, anxiety, and post-traumatic stress disorder comprising the step of administering a therapeutically effective quantity of a cholinergic M1 receptor antagonist and a therapeutically effective quantity of one or more cholinomimetic agents to lessen the symptoms of depression, anxiety, and post-traumatic stress disorder. Typically, the cholinergic M1 receptor antagonist is selected from the group consisting of telenzepine, amytriptyline, biperiden, trihexyphenidyl, darifenacin, dicyclomine, and tiotropium. Another aspect of the present invention is directed to methods and compositions employing other therapeutic agents and combinations of therapeutic agents for emulating the theoretical pharmacological effects of the non-selective mAChR antagonist scopolamine. The invention also encompasses pharmaceutical compositions incorporating one or more therapeutic agents and a pharmaceutically acceptable carrier.

A method of treating weight loss due to underlying disease in a patient the method comprising administering to the patient an effective amount of an agent which reduces sympathetic nervous system activity. A method of treating weight loss due to underlying disease in a patient the 10 method comprising administering to the patient an effective amount of any one or more of the following: a compound which inhibits the effect of aldosterone such as an aldosterone antagonist; a chymase inhibitor; a cathepsin B inhibitor; a 13 receptor blocker; an imidazoline receptor antagonist; a centrally acting tx receptor antagonist; a peripherally acting ct receptor antagonist; a ganglion blocking agent; a drug that has an effect on cardiovascular reflexes and thereby reduce SNS activity such as an opiate; scopolamine; an endothelin receptor antagonist; and a xanthine oxidase inhibitor. The methods are particularly useful in treating cardiac cachexia.

The invention relates to the application of microwave and ultrasonic technologies in synthesizing tiotropium bromide anhydride, in particular to a method for preparing the refined product of a finished product, namely, tiotropium bromide anhydride through crystallization and recrystallization processes by using a crude product of tiotropium bromide prepared through bromization reaction after hydrolytic reaction of scopolamine hydrobromide under microwave function, substitution and coupling reaction of bromothiophene, magnesium, and oxalic acid dimethyl ester under the microwave function, and condensation reaction of scopine and thiophen methyl glycollate under the microwave function. Using the invention to prepare tiotropium bromide anhydride, not only the reaction time is short, the side reaction is less, and the yield rate is high in the room temperature condition, but also the product quality is stable, controllable, safe and effective.

Provided herein are methods and compositions for the treatment of depression and anxiety. The compositions comprise scopolamine, or an analog thereof, and can optionally include one or more psychoactive agents. Further provided is an inhaler comprising scopolamine, or an analog thereof, in a pharmaceutically acceptable carrier.

An implant for use with an eye comprises an implantable structure and a therapeutic agent. The therapeutic agent is deliverable from the structure into the eye so as to therapeutically effect and / or stabilize a refractive property of the eye. In many embodiments, the refractive property of the eye may comprise at least one of myopia, hyperopia or astigmatism. The therapeutic agent can comprise a composition that therapeutically effects or stabilizes the refractive property of the eye. The therapeutic agent may comprise at least one of a mydriatic or a cycloplegic drug. For example, the therapeutic agent may include a cycloplegic that comprises at least one of atropine, cyclopentolate, succinylcholine, homatropine, scopolamine, or tropicamide. In many embodiments, a retention element can be attached to the structure to retain the structure along a natural tissue surface.

The invention provides an orally-disintegrating micropowder tablet for treating bacterial diarrhea of a young livestock. The orally-disintegrating micropowder tablet comprises the following components in parts by weight: 2-10 parts of norfloxacin, 5-30 parts of a liquorice extract and 25-120 parts of an orally-disintegrating auxiliary material; preferably, the orally-disintegrating micropowder tablet further comprises 0.02-0.5 part of scopolamine hydrobromide, 0.06-3 parts of potassium chloride, 0.1-2 parts of magnesium stearate, 0.01-1 part of sodium dodecyl sulfate, 0.01-0.5 part of sodium glycyrrhizinate, 0.01-0.5 part of cream essence or fresh milk essence and 0.05-0.5 part of sodium glutamate. The invention further provides a preparation method. The preparation method comprises the following steps: firstly, mixing the norfloxacin and the liquorice extract; secondly, dissolving the scopolamine hydrobromide, the potassium chloride and the sodium glutamate; thirdly, mixing the above substances into a paste; finally, adding other substances to prepare the orally-disintegrating micropowder tablet. The orally-disintegrating micropowder tablet can avoid the young livestock from generating a stress reaction, has a good sterilizing effect and can control bacterial toxin; the components can generate synergy to improve the therapeutic effect.

The present invention belongs to the field of medicine preparation, and is nasal in-situ gel of scopolamine with phase change property as one new kind of nasal medicine preparation form. The medicine preparation is prepared with scopolamine or its pharmaceutically acceptable salt or ester derivative, hydrophilic gel and pharmaceutically essential supplementary material. It is water solution of scopolamine containing environment sensitive polymer material, and is liquid at normal state and forms gel on the surface of nasal mucous membrane fast after nasal cavity administration. It has delayed medicine elimination, raised bioavailability, no preparation and use inconvenience like that of common high viscosity gel preparation and no toxicity on nasal cilium.

Non-effervescent pharmaceutical compositions having at least one particle of carbonate coated by a layer of polyethylene glycol that substantially covers the at least one carbonate particle are described. Compositions are also described where the compositions include a weakly basic therapeutic agent, a first pH-modifying agent having at least one particle of carbonate coated by a layer of polyethylene glycol, and a second pH-modifying agent. The weakly basic therapeutic agent could, but is not limited to, be zolpidem or scopolamine. Compositions including zolpidem and scopolamine are used to treat insomnia and depression, respectively.

A method of treating weight loss due to underlying disease in a patient, the method comprising administering to the patient an effective amount of an agent which reduces sympathetic nervous system activity. A method of treating weight loss due to underlying disease in a patient the method comprising administering to the patient an effective amount of any one or more of the following: a compound which inhibits the effect of aldosterone such as an aldosterone antagonist; a chymase inhibitor; a cathepsin B inhibitor; a β receptor blocker; an imidazoline receptor antagonist; a centrally acting α receptor antagonist; a peripherally acting α receptor antagonist; a ganglion blocking agent; a drug that has an effect on cardiovascular reflexes and thereby reduces SNS activity such as an opiate; scopolamine; an endothelin receptor antagonist; and a xanthine oxidase inhibitor. The methods are particularly useful in treating cardiac cachexia.

The use of extract form Wangla (coeloglossum viride (L) Hartm. Var. Bracteatum (Willd.) Richter), succinate derivative esters, and a derivative and pharmaceutical acceptable salts thereof, for the manufacture of a pharmaceutical preparation for the treatment of dementia, particularly for the treatment of Alzheimer' disease and Vascular dementia. Through Animal experiment, it has been demonstrated that, succinate derivative esters can improve learning and memory ability in dementia rats induced by scopolamine and cyclohexenyl imine; improve learning and memory ability in dementia rats induced by β-amyloid; improve learning and memory ability in dementia rats induced by permanent ligation of bilateral carotid; and improve memory ability of normal animals. It has the advantage of high activity, low toxicity and no inhibition to cholinesterase.

The invention relates to an atropa belladonna WRKY transcription factor gene and a recombinant plant expression vector and application thereof. The gene has a specific gene promoter activation role for synthesis of scopolamine, wherein the nucleotide sequence thereof is as shown in SEQ ID NO.3, and the coded amino acid sequence is as shown in SEQ ID NO.4. The AbWRKY1 gene is overexpressed in atropa belladonna, so that the content of scopolamine in atropa belladonna hairy root is increased, therefore, the gene can be applied to improvement of quality of the atropa belladonna, and can increase the content of scopolamine in the atropa belladonna.

The invention relates to a process for the isolation of compound scopoletin which is used as nitric oxide synthesis inhibitor from Artemisia annua and other plant families, said process comprising extraction of dried powdered material of different plant parts with an aqueous acetonitrite solvent in the ratio of 1:5 for 6 to 8 hrs., concentration of the extracted solvent upto 30% of its original extract under vacuum, partitioning the concentrated extract with halogenated solvent to transfer scopoletin in the non-polar halogenated solvent, drying halogenated solvent over anhydrous sodium sulphate and evaporating the solvent, crystallizing the residues in methanol and filtering the crystals, concentrating the filtrate and chromatographed on silica gel, eluting scopoletin in chloroform methanol mixture; and crystallization of the fractions containing the scopoletin to get the pure scopoletin compound.

The invention discloses a preparation method of scopolamine butylbromide, comprising the steps of: (1) subjecting scopolamine and n-butyl bromide to heating under reflux to complete reaction; (2) preparing a crude product of scopolamine butylbromide; and (3) refining the crude product of scopolamine butylbromide. By means of the invention, by utilizing the physicochemical property that n-butyl bromide has excellent dissolubility for scopolamine, but poor dissolubility for reaction product scopolamine butylbromide, the scopolamine and excessive n-butyl bromide are reacted, and thus the yield of scopolamine butylbromide is improved by raising reaction temperature, increasing reaction speed and shortening reaction time. In the preparation method of scopolamine butylbromide, disclosed by the invention, the use of any medium is avoided, the n-butyl bromide is not only used as a raw material for synthesizing scopolamine butylbromide, but also as a reaction solvent with stable properties, excessive n-butyl bromide can be recovered and treated relatively easily after the reaction is finished and can be repeatedly used, and thus, cost reduction is facilitated, and environment is protected.

Compositions comprising essentially of methscopolamine in combination with tannate compounds which are effective when administered orally for the symptomatic relief of symptoms associated with upper respiratory tract conditions such as the common cold, sinusitis, allergic rhinitis, and other upper respiratory tract conditions.

The invention discloses multiple-target effects of an isoflavone derivative and its application in improvement of learning and memory. Specifically, the invention discloses that a compound J39136 has the effects of: upregulating the expression of SIRT1 protein with damage repair and neuroprotective effects; inhibiting the activity of acetylcholinesterase and butyrylcholinesterase, and dose-dependently inhibiting the acetylcholinesterase activity of cells under a safe dose; protecting nerve cells, inhibiting abnormal expression of beta-APP, and reducing Abeta1-42 secretion; and regulating neuroinflammation. Animal experimental results prove that J39136 has low toxicity, can penetrate the blood-brain barrier, and can significantly improve scopolamine caused mouse dementia and strengthen learning and memory functions. Preclinical study results prompt that J39136 is expected to become the drug for prevention and / or treatment of learning and memory disorder and Alzheimer's disease.

The invention discloses a technology for extraction and separation of scopolamine from low content datura metel. The technology includes: adopting ultrasonic-assisted dichloromethane process for extraction, then using acid water and carbon tetrachloride for extraction to realize preliminary enrichment of scopolamine, and then combining macroporous resin with crystallization technology for purification to obtain high purity scopolamine hydrobromide. The technology has the advantages of low dosage of high toxic organic solvent, high purity and recovery product, strong enrichment and purificationeffect, large sample handling capacity, simple and feasible process, suitability for low content raw materials and the like.

The invention discloses a uses of procyanidins from lotus seedpod in preparation medicine for prevention of senile dementia and health care food. Specifically, relating to effects of procyanidins from lotus seedpod for the improvement of young mouse on learning and memory disorder caused by scopolamine and alcohol, also discussing its mechanism of action. Kunming mouse is taken as animal test in said invention, Y maze method adopted, testing the effect of procyanidins from lotus seedpod on learning and memory of the mouse, also testing brain tissue or content or activity of MDA, NO, NOS, SOD, AchE and MAO-B.

The invention discloses a drug combination used for improving cognitive function dysfunctions and treating senile dementia using ginseng, white paeony root and ginkgo leaves as raw materials. The invention also discloses the preparation method of the drug combination. The experiment confirms that the invention combination can significantly improve learning and memory ability of ageing rats dysmnesia caused by scopolamine, and meanwhile can increase acetylcholine content in the hippocampus of the subjective rats.

The invention provides a new compound (E)-1-(3,5-dimethoxyphenyl)-2-(3,5-dihydroxy-4-methoxyphenyl)ethylene disclosed as a structural formula I, and a preparation method thereof and application of the (E)-1-(3,5-dimethoxyphenyl)-2-(3,5-dihydroxy-4-methoxyphenyl)ethylene in the preparation of medicaments for preventing and / or treating neurodegenerative diseases. The test proves that the compound has a strong protective function on nerve cells and can obviously improve scopolamine-induced mouse learning dysmnesia, thereby possibly having a preventing and / or treating function on neurodegenerative diseases and further having application potential in the field of pharmacy.

The invention belongs to the technical field of traditional Chinese medicine and specifically provides a pharmaceutical composition for treating cognitive disorder. The pharmaceutical composition is composed of astragalus root, scutellaria baicalensis, rhizoma alismatis, salviae miltiorrhizae and ginseng. The invention also discloses a novel usage of the pharmaceutical composition in preparation of medicine for perfecting Alzheimer disease. The pharmaceutical composition provided by the invention can inhibit the expression of APP, A beta-40 and A beta-42 in a brain tissue, greatly improve the learning and memory ability of a quasi dementia mouse caused by scopolamine and reduce the ACHE activity of the brain tissue, so that the pharmaceutical composition provided by the invention has a good anti-dementia effect. In senile dementia treatment, the pharmaceutical composition provided by the invention can greatly improve the sugar metabolism of a dementia rat model and can also increase the contents of noradrenaline, dopamine and serotonin in pallium of a rapid brain aging mouse.

The invention relates to a composition, and also relates to a Crocus sativus pigment active site extracted from Fructus Gardeniae. The composition mainly comprises trans-crocetin di(beta-D-gentiobiosyl)ester, trans-crocetin-beta-D-gentiobiosyl-beta-D-glucosyl ester, trans-crocetin di(beta-D-glucosyl)ester, 13-cis-crocetin di(beta-D-gentiobiosyl)ester, neocrocin B, trans-crocetin mono(beta-D-gentiobiosyl)ester, 13-cis-crocetin-8-O-beta-D-gentiobiosyl ester, 13-cis-crocetin-8'-O-beta-D-gentiobiosyl ester and trans-crocetin mono(beta-D-glucosyl)ester. Pharmacological experiment results show that the Crocus sativus pigment active site can effectively improve mouse learning memory injuries induced by scopolamine and amyloid beta protein.

The invention provides a synthesis method and a detection method for scopolamine derivatives. The synthesis method comprises the following steps that: under the existence of carbonate, bicarbonate or other alkaline matter, quaternization reaction is carried out to scopolamine and halogenated hydrocarbon or halogen olefin; dehydration treatment is carried out to reactants and solvent before the reaction; when the reaction begins, the alkaline matter which is two times the molar weight of the scopolamine is added; when the reaction is carried out for four hours, the alkaline matter is filtered out, and filtrate continues to react; the solvent is selected from any one or mixture of ethanol, methanol and acetonitrile. The detection method comprises the following steps that: the content of scopolamine derivatives is determined through high performance liquid chromatography; a mobile phase preparation method is to mix methanol or acetonitrile with ammonium salt buffer solution according to the proportion of 20-50:80-50; the ammonium salt buffer solution respectively uses formic acid, glacial acetic acid or phosphoric acid to regulate ammonium formate, ammonium acetate or ammonium dihydrogen phosphate with the pH value less then 4; flow rate is between 0.5 and 2.0 ml / min; the absorption is detected at a position with the wavelength between 210 and 250 nanometers.

The invention relates to a medicinal composition, in particular to a composition comprising 4-hydroxyl-2-oxo-1-pyrrolidine acetamine and 2-borneol, and application of the composition in medicines for preventing and / or treating cognition impairment. The composition provided by the invention can remarkably improve a cerebral trauma neural function of a rat and can remarkably prolong the time of passive activities. The composition provided by the invention plays a role in improving dysmnesia of the rat, caused by scopolamine, and can remarkably improve cognitive disorder of the rat, caused by cerebral ischemia. The composition has a remarkable effect in preventing and / or treating cognition impairment.

The invention provides the application of lamiophlomis rotate total glycosides to preparing medicines, i.e. the application of lamiophlomis rotate total glycosides to preparing medicines for preventing and / or treating senile dementia. Shown by pharmacodynamic experimental results, the lamiophlomis rotate total glycosides have obvious memory improvement effect on mouse memory acquisition impairment caused by scopolamine, have obvious effect on improving the learning and memory functions of mice with the learning dysmnesia caused by cerebral ischemia reperfusion and can be clinically used for resisting aging and preventing and / or treating the senile dementia. The medicines of the invention has easily obtained raw materials, are easy to be industrialized, can be made into various preparations according to needs to provide clinical use with modern Chinese medicines with more convenient use, better curative effect, more controllable quality, and bring patients with more benefits so as to generate gigantic social benefits.

The invention discloses a medical composition for treating piglet diarrhea, comprising the following raw materials in parts: 50-100 parts of neomycin sulfate, 10-50 parts of scopolamine methobromide, 100-150 parts of montmorillonite, 1-5 parts of VB1, 1-5 parts of VB2, 1-5 parts of VB6, 10-50 parts of nicotinamide, 10-50 parts of calcium pantothenate, 1-10 parts of sodium chloride, 1-12 parts of sodium bicarbonate, 1-10 parts of potassium chloride and 100-150 parts of anhydrous dextrose. The medical composition disclosed by the invention is used for treating piglet diarrhea and dehydration caused by diarrhea, so that morbidity and mortality of the piglet diarrhea are effectively prevented and controlled.

The invention provides an application of (E)-N-[2-(3,4-dimethoxyphenyl)ethyl]-3-phenylacrylamide compound 1 in preparation for a medicine resisting Alzheimer disease. An animal experiment for the nerve cells of a primary SD rat displays that: the compound 1 can be bound with alpha7nAChR, and the binding site is as the same as the binding site of bungatotoxin. Anti-inflammatory activity experiment prompts that the compound 1 has good anti-inflammatory activity. The compound 1 remarkably improves the toxicity of the nerve cells of the primary SD rat, and has a neuroprotective effect. Moreover, the compound 1 can directly act on amyloid protein, so as to achieve reduction for the toxic effect on the nerve cells acted by beta-amyloid. An experiment of treating a mouse by scopolamine indicates that the compound 1 can effectively improve the learning ability and the memory ability of experimental animal. The experiment shows that the compound 1 can effectively treat the senile dementia induced by beta-amyloid by means of exciting alpha7-acetylcholine receptor, depolymerizing beta-amyloid and the like. Therefore, the compound 1 can be used for preparing a medicine resisting Alzheimer disease, and has great clinical application value.